A J Czaja

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Current therapy for autoimmune hepatitis
    Aldo J Montano Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Nat Clin Pract Gastroenterol Hepatol 4:202-14. 2007
  2. doi request reprint Autoimmune hepatitis. Part A: pathogenesis
    Albert J Czaja
    Mayo Clinic, 200 First Street S W, Rochester, Minnesota 55905, USA
    Expert Rev Gastroenterol Hepatol 1:113-28. 2007
  3. ncbi request reprint Diagnosis and management of the overlap syndromes of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Can J Gastroenterol 27:417-23. 2013
  4. ncbi request reprint Current management strategies for hepatocellular carcinoma
    A J Czaja
    Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester, MN, USA
    Minerva Gastroenterol Dietol 59:143-59. 2013
  5. doi request reprint Hepatocellular carcinoma and other malignancies in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 58:1459-76. 2013
  6. doi request reprint Autoimmune hepatitis in diverse ethnic populations and geographical regions
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 7:365-85. 2013
  7. ncbi request reprint Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part II
    Albert J Czaja
    Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Inflamm Allergy Drug Targets 11:351-63. 2012
  8. ncbi request reprint Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I
    Albert J Czaja
    Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Inflamm Allergy Drug Targets 11:337-50. 2012
  9. doi request reprint Drug choices in autoimmune hepatitis: part A--Steroids
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 6:603-15. 2012
  10. doi request reprint Drug choices in autoimmune hepatitis: part B--Nonsteroids
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905 USA
    Expert Rev Gastroenterol Hepatol 6:617-35. 2012

Collaborators

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint Current therapy for autoimmune hepatitis
    Aldo J Montano Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Nat Clin Pract Gastroenterol Hepatol 4:202-14. 2007
    ....
  2. doi request reprint Autoimmune hepatitis. Part A: pathogenesis
    Albert J Czaja
    Mayo Clinic, 200 First Street S W, Rochester, Minnesota 55905, USA
    Expert Rev Gastroenterol Hepatol 1:113-28. 2007
    ..Autoimmune hepatitis is a model of autoreactivity that reflects multiple disturbances in the counter-regulatory mechanisms essential for immune homeostasis...
  3. ncbi request reprint Diagnosis and management of the overlap syndromes of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Can J Gastroenterol 27:417-23. 2013
    ..Autoimmune hepatitis may have cholestatic features that are outside the classical phenotype and that resemble findings in other immune-mediated liver diseases. These cholestatic phenotypes have been designated 'overlap syndromes'...
  4. ncbi request reprint Current management strategies for hepatocellular carcinoma
    A J Czaja
    Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester, MN, USA
    Minerva Gastroenterol Dietol 59:143-59. 2013
    ..In regions with limited resources, strong preventive measures must be instituted and at least hepatic resection or tumor ablation must be developed. ..
  5. doi request reprint Hepatocellular carcinoma and other malignancies in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 58:1459-76. 2013
    ..Surveillance recommendations have not been promulgated, but hepatic ultrasonography every six months in patients with cirrhosis is a consideration. Routine health screening measures for other malignancies should be applied diligently...
  6. doi request reprint Autoimmune hepatitis in diverse ethnic populations and geographical regions
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 7:365-85. 2013
    ..Ethnic-based deviations from classical phenotypes and the frequency of late-stage disease can complicate the diagnosis and management of autoimmune hepatitis in non-white populations...
  7. ncbi request reprint Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part II
    Albert J Czaja
    Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Inflamm Allergy Drug Targets 11:351-63. 2012
    ..Development of these feasible new interventions for autoimmune hepatitis requires therapeutic animal models, societal support, and a collaborative network of investigators to conduct rigorous clinical trials...
  8. ncbi request reprint Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I
    Albert J Czaja
    Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Inflamm Allergy Drug Targets 11:337-50. 2012
    ..None has been licensed for use in autoimmune hepatitis, and their applications have been based on results from small singlecenter experiences...
  9. doi request reprint Drug choices in autoimmune hepatitis: part A--Steroids
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 6:603-15. 2012
    ..It is emerging as a frontline treatment, especially for noncirrhotic patients with uncomplicated disease...
  10. doi request reprint Drug choices in autoimmune hepatitis: part B--Nonsteroids
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905 USA
    Expert Rev Gastroenterol Hepatol 6:617-35. 2012
    ..The nonstandard, nonsteroidal medications are mainly salvage therapies with off-label indications that must be used in highly individualized and well-monitored clinical situations...
  11. doi request reprint Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 57:2248-66. 2012
    ..The substitution of mycophenolate mofetil for azathioprine and switch of the calcineurin inhibitor or its replacement with rapamycin have also been used for refractory disease. Re-transplantation has been necessary in 8-23 %...
  12. doi request reprint Advances in the current treatment of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 57:1996-2010. 2012
    ..Standard treatment regimens for autoimmune hepatitis can be upgraded without adjustments that require major new expertise...
  13. doi request reprint Autoantibody-negative autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 57:610-24. 2012
    ..The pathogenic mechanisms are presumed to be identical to those of classical disease. Autoantibody-negative autoimmune hepatitis is an infrequent but treatable disease that must be considered in unexplained acute and chronic hepatitis...
  14. ncbi request reprint Progress in the diagnosis and treatment of autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester, MN 55905, USA
    Minerva Med 99:549-68. 2008
    ..Progress has been made in the diagnosis and treatment of autoimmune hepatitis, but more work must be done. Multicenter clinical trials are essential before the incorporation of new drugs into the treatment algorithm...
  15. doi request reprint Features and consequences of untreated type 1 autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Int 29:816-23. 2009
    ..The existence of a mild form of autoimmune hepatitis that does not require treatment remains controversial. The aim of this study was to determine the existence, characteristics and outcome of this form...
  16. doi request reprint Performance parameters of the diagnostic scoring systems for autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 48:1540-8. 2008
    ....
  17. ncbi request reprint Safety issues in the management of autoimmune hepatitis
    Albert J Czaja
    Mayo Clinic and Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, 200 First Street SW, Rochester, Minnesota 55905, USA
    Expert Opin Drug Saf 7:319-33. 2008
    ..Prednisone and azathioprine are effective in the treatment of autoimmune hepatitis, but diverse side effects can diminish their net benefit...
  18. ncbi request reprint Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs Aging 25:219-39. 2008
    ..Treatment failure is uncommon in the elderly, and age-related changes in the cellular immune response may attenuate the disease and enhance its response to therapy. Concurrent adjuvant therapies must focus on maintenance of bone density...
  19. doi request reprint Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 6:379-88. 2008
    ..These lessons may be applicable to autoimmune disease in general...
  20. doi request reprint Arthur Joseph McCullough, Jr., 58th President, AASLD
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Hepatology 47:775-6. 2008
  21. ncbi request reprint Optimizing diagnosis from the medical liver biopsy
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:898-907. 2007
    ..Neoplastic changes typically are cytologic transformations rather than injury patterns, and they are not discussed here...
  22. ncbi request reprint HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 53:522-8. 2008
    ..01). Only patients with primary sclerosing cholangitis had a comparable occurrence of HLA DRB1*13. In conclusion, HLA DRB1*13 may be a genetic risk factor for some white North American patients with type 1 autoimmune hepatitis...
  23. ncbi request reprint Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Minerva Gastroenterol Dietol 53:43-78. 2007
    ..Confident animal models of the human disease and a collaborative network of clinical investigators are the requisites for progress...
  24. ncbi request reprint Autoimmune liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Gastroenterol 23:255-62. 2007
    ..The aim of this article is to review studies that improve the diagnosis and treatment of autoimmune hepatitis and suggest new drug and molecular interventions...
  25. ncbi request reprint Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Pharm Des 17:3120-40. 2011
    ....
  26. ncbi request reprint Autoimmune liver disease and rheumatic manifestations
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Rheumatol 19:74-80. 2007
    ..To review studies that clarify the rheumatic manifestations of autoimmune hepatitis, elucidate shared pathogenic pathways, and encourage innovative site-specific therapies...
  27. ncbi request reprint Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Dig Dis Sci 51:968-75. 2006
    ..We conclude that routine screening of blood thiopurine methyltransferase levels has a low yield for identifying individual patients at risk for azathioprine toxicity during conventional low dose therapy for autoimmune hepatitis...
  28. doi request reprint Autoimmune hepatitis. Part B: diagnosis
    Albert J Czaja
    Mayo Clinic, 200 First Street S W, Rochester, Minnesota 55905, USA
    Expert Rev Gastroenterol Hepatol 1:129-43. 2007
    ..Variant syndromes should be suspected if cholestatic features are prominent and conventional treatment is ineffective...
  29. doi request reprint Autoimmune liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Gastroenterol 25:215-22. 2009
    ..To review studies that improve the diagnosis and treatment of autoimmune hepatitis and extend the understanding of its pathogenic mechanisms...
  30. doi request reprint Cryptogenic chronic hepatitis and its changing guise in adults
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 56:3421-38. 2011
    ..The 1- and 5-year survivals after liver transplantation have ranged from 72-85% to 58-73%, respectively...
  31. doi request reprint Drug-induced autoimmune-like hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Dig Dis Sci 56:958-76. 2011
    ..Relapse after corticosteroid withdrawal probably does not occur, and its absence distinguishes drug-induced disease from classical autoimmune hepatitis...
  32. doi request reprint Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 140:1472-80. 2011
    ..A retrospective study was performed to determine the bases for the classification of probable autoimmune hepatitis and its clinical importance...
  33. doi request reprint Performance parameters of the conventional serological markers for autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Dis Sci 56:545-54. 2011
    ..Autoimmune hepatitis is defined by a conventional battery of autoantibodies that may also be present in other liver diseases...
  34. doi request reprint Putting flesh and polish on autoimmune hepatitis and moving the disease of exclusion to inclusion
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 52:1177-84. 2010
    ..Autoimmune hepatitis exemplifies an evolutionary process in the science of autoimmunity and the people committed to its study. Lessons derived from this experience can be far-reaching...
  35. doi request reprint Animal models of autoimmune hepatitis
    Albert J Czaja
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 4:429-43. 2010
    ..Vaccination or infection of murine models with viral vectors carrying human antigens are the most recent developments. Animal models promise to extend the knowledge of etiological agents and improve treatment algorithms...
  36. ncbi request reprint The role of autoantibodies as diagnostic markers of autoimmune hepatitis
    Albert J Czaja
    Mayo Clinic, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    Expert Rev Clin Immunol 2:33-48. 2006
    ....
  37. doi request reprint Autoantibodies as prognostic markers in autoimmune liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Dis Sci 55:2144-61. 2010
    ..Progress has been made in identifying the serological markers of prognosis in autoimmune liver disease, and they promise to reflect critical disease mechanisms and enhance patient management...
  38. doi request reprint Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 139:58-72.e4. 2010
    ..Identification of the key defects in immune homeostasis and antigen targets will direct new therapies...
  39. doi request reprint Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Dis Sci 55:1761-9. 2010
    ..Relapse of autoimmune hepatitis after corticosteroid withdrawal is common, but the outer limit for this occurrence and the appropriate post-treatment surveillance strategy are uncertain...
  40. pmc Difficult treatment decisions in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    World J Gastroenterol 16:934-47. 2010
    ....
  41. doi request reprint Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Liver Dis 29:315-30. 2009
    ..The special clinical challenges are essential to recognize and treat properly, and they may also extend hypotheses of pathogenesis...
  42. doi request reprint Current and future treatments of autoimmune hepatitis
    Albert J Czaja
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Rev Gastroenterol Hepatol 3:269-91. 2009
    ....
  43. doi request reprint Rapidity of treatment response and outcome in type 1 autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    J Hepatol 51:161-7. 2009
    ..Corticosteroid therapy is effective in type 1 autoimmune hepatitis. This study determines if the rapidity of response affects outcome...
  44. doi request reprint Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Dis Sci 55:2712-26. 2010
    ..Progress in the development of an animal model of autoimmune hepatitis and experiences in other immune-mediated diseases justify the evaluation of site-specific molecular and cellular interventions in this disease...
  45. ncbi request reprint Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Int 26:552-8. 2006
    ..To determine the clinical phenotype and outcome of patients with definite type 1 autoimmune hepatitis, who lack human leukocyte antigen (HLA) DR3 and DR4, and to assess the importance of HLA DR7 and DR13...
  46. ncbi request reprint Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Hepatology 30:1381-6. 1999
    ..Short-term therapy, however, does not facilitate reduction in the dose of corticosteroids or its withdrawal, affect clinical outcome, or reduce histological activity...
  47. ncbi request reprint Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Liver Int 23:116-23. 2003
    ..Relapse of type 1 autoimmune hepatitis after drug withdrawal may relate to incomplete histological improvement during corticosteroid therapy and/or persistence of pathogenic mechanisms...
  48. ncbi request reprint Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street S W Rochester, MN 55905, USA
    Autoimmunity 35:475-83. 2002
    ..Antibodies to soluble liver antigen/liver pancreas are highly specific markers of autoimmune hepatitis...
  49. ncbi request reprint Autoantibodies in the diagnosis and management of liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Clin Gastroenterol 37:315-29. 2003
    ..These advances may in turn clarify pathogenic mechanisms, facilitate the development of animal models, and generate novel site-specific therapies...
  50. ncbi request reprint Emerging treatments for autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Drug Targets Inflamm Allergy 1:317-26. 2002
    ..Critical mechanisms of immunocyte activation, cytotoxic T cell expansion, and cytokine modulation are the targets of site-specific interventions...
  51. ncbi request reprint Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Hepatol 40:646-52. 2004
    ..Our goal was to determine changes in fibrosis and the frequency of histological cirrhosis in corticosteroid-treated autoimmune hepatitis (AIH)...
  52. ncbi request reprint Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Hepatology 39:1631-8. 2004
    ..Progression is associated with HLA DR3/DR4 and worsening histological activity. Exacerbations or persistence of disease activity does not increase disease progression after treatment has been instituted...
  53. ncbi request reprint Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street S W, Rochester, Minnesota 55905, USA
    Dig Dis Sci 49:611-8. 2004
    ..They may be associated with non-disease-specific immune responses, but they do not define individuals with a distinctive clinical phenotype, associated mucosal diseases, or treatment outcome...
  54. ncbi request reprint Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Liver Int 24:322-9. 2004
    ..Bile duct injury is not a feature of classical autoimmune hepatitis (AIH), but it has been described in variant forms of the disease...
  55. ncbi request reprint Treatment of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Semin Liver Dis 22:365-78. 2002
    ....
  56. ncbi request reprint Treatment strategies in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Liver Dis 6:799-824. 2002
    ..Investigational therapies promise to target critical pathogenic mechanisms affecting immunocyte activation, autoantigen recognition, cytokine interactions, and regenerative activity...
  57. ncbi request reprint Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Hepatol 37:302-8. 2002
    ....
  58. ncbi request reprint Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Immunol Rev 174:250-9. 2000
    ..These additional MHC encoded genes and other non-MHC encoded genes may be important determinants of disease susceptibility and severity in type 1 autoimmune hepatitis...
  59. ncbi request reprint Autoimmune cholangitis within the spectrum of autoimmune liver disease
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Hepatology 31:1231-8. 2000
    ..It may represent variant forms of diverse conditions, a transition stage, or a separate entity with varying manifestations...
  60. ncbi request reprint Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1312-6. 2000
    ..Our goals were to assess budesonide in patients with treatment-dependent autoimmune hepatitis and to determine if efficacy and safety justified a controlled trial...
  61. ncbi request reprint Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Gastroenterology 117:645-52. 1999
    ..Polymorphisms that control cytokine production can affect immunoregulation. The frequency and consequences of these polymorphisms in type 1 autoimmune hepatitis were determined...
  62. ncbi request reprint Autoimmune hepatitis with incidental histologic features of bile duct injury
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Hepatology 34:659-65. 2001
    ..They may be coincidental findings associated with classic disease or weak expressions of a variant syndrome. In the absence of a cholestatic clinical syndrome, they do not compel a different management strategy...
  63. ncbi request reprint Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Hepatology 35:890-7. 2002
    ..All patients are candidates for this outcome, and withdrawal of medication, even during maintenance schedules, is necessary to assess its likelihood...
  64. ncbi request reprint Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Liver Transpl 8:505-13. 2002
    ..The mechanisms that perturb immunologic homeostasis in this human model of the classical disease must be studied more rigorously...
  65. ncbi request reprint Diagnosis and treatment of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Hepatology 36:479-97. 2002
  66. ncbi request reprint Autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW Rochester, MN 55905, USA
    Clin Liver Dis 6:xi-xii. 2002
  67. ncbi request reprint Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Gastroenterol 39:819-25. 2005
    ..To assess the outcomes of empiric therapy with mycophenolate mofetil in patients with autoimmune hepatitis...
  68. ncbi request reprint Autoimmune liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Gastroenterol 21:293-9. 2005
    ..This review aims to demonstrate how recent insights into disease behavior and mechanisms and the availability of new drugs can be assimilated into evolving concepts of diagnosis and treatment...
  69. doi request reprint Autoimmune liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Curr Opin Gastroenterol 24:298-305. 2008
    ..To review studies that improve the diagnosis and treatment of autoimmune hepatitis and extend understanding of its pathogenic mechanisms...
  70. ncbi request reprint Autoimmune liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Curr Opin Gastroenterol 22:234-40. 2006
    ..To review studies that improve the diagnosis and treatment of autoimmune hepatitis and presage new drug and molecular site-specific interventions...
  71. ncbi request reprint Treatment challenges and investigational opportunities in autoimmune hepatitis
    Albert J Czaja
    Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, MN 55905, USA
    Hepatology 41:207-15. 2005
    ..In conclusion, evolving pharmacological and technical advances promise to improve the treatment of autoimmune hepatitis, and investigations of these advances are timely, feasible, and necessary...
  72. ncbi request reprint Diverse manifestations and evolving treatments of autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Minerva Gastroenterol Dietol 51:313-33. 2005
    ..Better prognostic indices, new immunosuppressive agents, and site-specific molecular interventions promise to improve care...
  73. ncbi request reprint Current concepts in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Ann Hepatol 4:6-24. 2005
    ..New immunosuppressive agents and site-specific interventions promise to improve care...
  74. ncbi request reprint Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:532-8. 2006
    ..Transitions in clinical and genetic phenotypes occur after age > or = 40 years. Genetic susceptibilities may favor etiologic factors that are age-related...
  75. doi request reprint Autoimmune hepatitis in special patient populations
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Gastroenterol 25:689-700. 2011
    ..Pregnancy is usually well-tolerated by mother and foetus but requires protection against postpartum exacerbation. Special populations must be recognized and treated with tailored regimens...
  76. ncbi request reprint Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis
    Aldo Montano-Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Autoimmunity 39:341-8. 2006
    ..Determine the frequency, clinical phenotype, and prognostic implications of antibodies against cyclic citrullinated peptides in patients with type 1 autoimmune hepatitis...
  77. ncbi request reprint Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:413-9. 2002
    ..Our aim was to determine if these antibodies are reflective of a genetic predisposition for recrudescent disease...
  78. ncbi request reprint Frequency and significance of antibodies to chromatin in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Dig Dis Sci 48:1658-64. 2003
    ..Percent positivity is greater in men than women, and seropositivity identifies individuals who commonly relapse after drug withdrawal...
  79. ncbi request reprint Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:2051-7. 2002
    ..Our goals were to determine the effect of gender on the clinical features and treatment outcome of type 1 autoimmune hepatitis, and to assess synergisms with the known genetic risk factors...
  80. ncbi request reprint Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse
    Aldo J Montano-Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Gastroenterol 102:1005-12. 2007
    ..Our goal was to refine treatment end point criteria so as to reduce the frequency of relapse after drug withdrawal...
  81. ncbi request reprint Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease
    Aldo J Montano-Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 46:1138-45. 2007
    ..3 points, P < 0.0001), and score greater than 12 points had greater sensitivity (97%) and specificity (68%) for treatment failure than did HLA DRB1*03 or other features...
  82. pmc Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis
    M Costa
    Department of Immunology, Sant Pau Hospital, Barcelona, Spain, and Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Clin Exp Immunol 121:364-74. 2000
    ....
  83. ncbi request reprint Consequences of treatment withdrawal in type 1 autoimmune hepatitis
    Aldo J Montano-Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Int 27:507-15. 2007
    ..Our goals were to determine whether relapse is associated with disease progression and whether treatment end points can be refined...
  84. pmc HLA DQ gene dosage and risk and severity of celiac disease
    Joseph A Murray
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:1406-12. 2007
    ..The aim of this study was to examine the role of DQA and DQB alleles in determining the risk for and the age of onset and severity of CD in an American population...
  85. ncbi request reprint Genetic bases of autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Dig Dis Sci 47:2139-50. 2002
    ..We conclude that autoimmune hepatitis is a model by which to study the genetic bases of autoimmunity...
  86. ncbi request reprint Nonstandard antibodies as prognostic markers in autoimmune hepatitis
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street S W, Rochester, MN 55905, USA
    Autoimmunity 37:195-201. 2004
    ..Antibodies to actin, chromatin, soluble liver antigen/liver pancreas and liver cytosol type 1 have been ascribed prognostic value in autoimmune hepatitis...
  87. doi request reprint Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis
    Aldo J Montano-Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    J Clin Gastroenterol 42:1047-53. 2008
    ..Antimitochondrial antibodies (AMA) can occur in autoimmune hepatitis, but their durability and prognostic significance are uncertain...
  88. ncbi request reprint The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants
    Herschel A Carpenter
    Department of Laboratory Medicine and Pathology, Mayo Medical School, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Liver Dis 6:685-705. 2002
    ..Conditions in which the histologic findings suggest the overlap of two disorders or are insufficient for designation as classic disease constitute the variant syndromes...
  89. ncbi request reprint Shared genetic risk factors in autoimmune liver disease
    A J Czaja
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Dig Dis Sci 46:140-7. 2001
    ..We conclude that patients with shared genetic risk factors do not have characteristic features nor do they have overlap syndromes. DR4 may be protective against primary sclerosing cholangitis...
  90. ncbi request reprint Understanding the pathogenesis of autoimmune hepatitis
    A J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905, USA
    Am J Gastroenterol 96:1224-31. 2001
    ..Findings can then be integrated into a comprehensive knowledge base that may be applicable to other autoimmune diseases...
  91. doi request reprint Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis
    Aldo J Montano-Loza
    Division of Gastroenterology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 103:1944-51. 2008
    ..Hepatocellular carcinoma (HCC) is an uncommon but serious occurrence in autoimmune hepatitis. Our objective was to determine predictors for this neoplasm to improve screening strategies...
  92. ncbi request reprint Recurrent autoimmune hepatitis after orthotopic liver transplantation
    A Gonzalez-Koch
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Liver Transpl 7:302-10. 2001
    ..HLA-DR3- or HLA-DR4-positive recipients are at risk for recurrence regardless of donor HLA status...
  93. ncbi request reprint Autoantibodies in autoimmune liver disease
    Albert J Czaja
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Adv Clin Chem 40:127-64. 2005
    ..Over-interpretation is the major pitfall in the clinical application of the serological results. New autoantibodies will emerge as the search for target antigens and key pathogenic pathways continues...
  94. ncbi request reprint Anti-tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs
    Antoni Xavier Torres-Collado
    Department of Immunology, Hospital de la Santa Creu i Sant Pau, Avnda S Antoni Ma Claret 167, 08025 Barcelona, Spain
    Liver Int 25:410-9. 2005
    ..8 kDa protein and identified with soluble liver antigen (SLA) and liver-pancreas (LP) antigen. The aim of this paper was to determine the best assay by which to detect these antibodies in type 1 AIH...
  95. ncbi request reprint Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries
    Albert J Czaja
    J Hepatol 44:251-2. 2006
  96. ncbi request reprint Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis
    Aldo J Montano-Loza
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Liver Int 26:1201-8. 2006
    ..HLA DRB1*03-DRB1*04 combines both susceptibility factors for type-1 autoimmune hepatitis...
  97. ncbi request reprint Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation
    Albert J Czaja
    Liver Transpl 13:953-5. 2007
  98. ncbi request reprint Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis
    Peter T Donaldson
    Centre for Liver Research, School of Clinical Medical Sciences, University of Newcastle, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
    Clin Liver Dis 6:707-25. 2002
    ..Under these circumstances, genetic studies may be the most practical, low risk means to investigate the pathogenesis of type 1 AIH and many other autoimmune diseases...
  99. ncbi request reprint Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C
    Paolo Muratori
    Department of Internal Medicine, Cardioangiology, Hepatology, Policlinico Sant Orsola Malpighi, Bologna, Italy
    Dig Dis Sci 52:179-84. 2007
    ..HLA DR11 may be protective against the development of microsomal antibodies in Italian patients, whereas HLA DR4, HLA DR13, and the B8-DR3-DQ2 haplotype may be protective in North American patients...
  100. doi request reprint Simplified criteria for the diagnosis of autoimmune hepatitis
    Elke M Hennes
    Department of Medicine, University Medical Centre Hamburg Eppendorf, Germany
    Hepatology 48:169-76. 2008
    ..Based on the ROC curves, two cutoff points were chosen. The score was found to have 88% sensitivity and 97% specificity (cutoff > or =6) and 81% sensitivity and 99% specificity (cutoff > or =7) in the validation set...
  101. ncbi request reprint Celiac disease-associated autoimmune cholangitis
    Robert E Sedlack
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:3196-8. 2002
    ..CD should be considered in all patients diagnosed with autoimmune cholangitis as a gluten-free diet may avoid the need for immunosuppressive therapy in affected patients...